最新ニュース ThredUp (NASDAQ:TDUP) 株価情報

THREDUP INC - CLASS A

ThredUp

ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.

ThredUp Inc

Mizuho Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFG#NYSE">MFG</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $2.51 by 99.2 percent. This is a 95.92 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $12.83 billion which missed the analyst consensus estimate of $671.67 billion by 98.09 percent. This is a 26.31 percent decrease over sales of $17.41 billion the same period last year.

Earnings

Earnings Misses

News

Mizuho Financial Gr Q4 EPS $0.02 Misses $2.51 Estimate, Sales $12.83B Miss $671.67B Estimate

WIIM

AYTU

Aytu BioPharma shares are trading higher after the company reported better-than-expected Q3 financial results.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/14/final-trades-apollo-global-goldman-sachs-taiwan-semi-and-zoom-communications.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington, managing partner at Requisite Capital Management, said Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) reported strong fee-related earnings. &#8220;I think the stock can <a href="https://www.benzinga.com/quote/APO/earnings">be in the 150s,&#8221; she added.</a>
On May 2, Apollo Global Management posted stronger-than-expected revenue for the first quarter.
Jason Snipe, Chief Investment Officer of Odyssey Capital Advisors, said he likes The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), which has gained 20% in the last month.
On the earnings front, Goldman Sachs Group posted better-than-expected earnings for its first quarter on April 14. Goldman Sachs reported quarterly earnings of $14.12 per share, which beat the analyst consensus estimate of $12.35 per share. The company reported quarterly sales of $15.06 billion, which beat the analyst consensus estimate of $14.81 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) reported a &#8220;phenomenal&#8221; quarter, and the stock is still going higher.
On April 17, Taiwan Semiconductor reported better-than-expected first-quarter financial results and issued a strong second-quarter revenue outlook.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, named Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) his final trade.
Zoom Communications announced it will release its financial results for the first quarter on Wednesday, May 21, after the closing bell.
Price Action:
<ul class="wp-block-list">
<li>Apollo Global shares fell 0.6% to close at $144.24 on Wednesday.</li>
<li>Goldman Sachs shares rose 1.3% to settle at $611.60 during Wednesday's session.</li>
<li>Taiwan Semiconductor Manufacturing shares gained 0.4% to close at $194.76 on Wednesday.</li>
<li>Zoom Communications shares rose 0.1% to $83.27 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

Markets

Media

Trading Ideas

Apollo Global, Taiwan Semiconductor Manufacturing, Zoom And A Big Bank On CNBC's 'Final Trades'

Toyo Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) reported quarterly earnings of $1.09 per share. This is a 354.17 percent increase over earnings of $0.24 per share from the same period last year. The company reported $176.96 million in sales this quarter. This is a 183.87 percent increase over sales of $62.34 million the same period last year.

TOYO

Toyo Co FY EPS $1.09 Up From $0.24 YoY, Sales $176.96M Up From $62.34M YoY

CLIK

Click Holdings shares are trading higher after the company announced it signed a cooperation agreement with Flash Mutual Technology.

Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6099 per pre-funded warrant share in an underwritten registered direct offering to a limited number of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture and Redmile Group. The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance. The offering is expected to close on or about May 16, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering are expected to be $16 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Atara. Atara currently intends to use the net proceeds from the offering to fund its ongoing activities required to achieve biologics license application (BLA) approval for tab-cel, and for working capital and general corporate purposes.

ATRA

Atara Biotherapeutics Prices Offering Of 834,237 Shares At $6.61/Shr And Pre-Funded Warrants At $6.6099 Per Pre-Funded Warrant Share In Underwritten Registered Direct Offering

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.95%</li>
<li>Morgan Stanley analyst Megan Alexander maintained an Equal-Weight rating and cut the price target from $31 to $29 on May 1, 2025. This analyst has an accuracy rate of 66%.</li>
<li>RBC Capital analyst Sabahat Khan maintained a Sector Perform rating and cut the price target from $54 to $34 on April 30, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On April 29, Polaris reported a first-quarter adjusted loss of 90 cents per share, beating the street view of 91 cents loss.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PII <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="907" height="682" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065356/image-176.png" alt="" class="wp-image-916328" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065356/image-176.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065356/image-176-300x226.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065356/image-176-768x577.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Dine Brands Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.27%</li>
<li>Barclays analyst Jeff Kessler maintained an Equal-Weight rating and raised the price target from $21 to $24 on May 8, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Keybanc analyst Eric Gonzalez maintained an Overweight rating and cut the price target from $30 to $26 on May 8, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On May 14, Dine Brands Global declared a quarterly cash dividend of 51 cents per share of common stock.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">latest DIN news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="930" height="815" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065430/image-177.png" alt="" class="wp-image-916330" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065430/image-177.png 930w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065430/image-177-300x263.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065430/image-177-768x673.png 768w" sizes="(max-width: 930px) 100vw, 930px" /></a></figure>
<h3 class="wp-block-heading">Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.17%</li>
<li>Goldman Sachs analyst Brooke Roach maintained a Sell rating and raised the price target from $4 to $4.5 on May 2, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained an In-Line rating and cut the price target from $9 to $8 on May 2, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On May 13, Kohl&#8217;s announced a proposed private offering of senior secured notes.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">KSS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="865" height="693" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065506/image-178.png" alt="" class="wp-image-916331" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065506/image-178.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065506/image-178-300x240.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15065506/image-178-768x615.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

Legendary investor&nbsp;Warren Buffett&nbsp;attributes much of his wealth accumulation to the fact that he is American. He reiterated his strong belief in the U.S. economy, brushing aside worries over potential transformative shifts. 
What Happened: During the annual Berkshire Hathaway shareholders meeting earlier this month, Buffett, who has amassed his wealth through U.S. stocks, responded by reasserting his faith in the country. &#8220;We&#8217;re always in the process of change and we&#8217;ll always find all kinds of things to criticize in the country. But the luckiest day in my life is the day I was born, because I was born in the United States,&#8221; he <a href="https://www.cnbc.com/2025/05/08/the-luckiest-day-of-my-life-warren-buffett-on-being-born-in-the-usa.html#:~:text=the%20audience%20member%20asked%2C%20via,United%20States%2C%22%20Buffett%20said">told </a>CNBC.
Buffett has consistently shown confidence in the U.S. economy, even during the 2007-2009 financial crisis when investors fled from U.S. stocks. Back in 2008, Buffett also wrote an Op-Ed in The New York Times titled &#8220;Buy American. I Am,&#8221; where he urged investors to hold tight during times of crisis and revealed that his personal account only had American assets due to a firm faith in the economy.
Despite recognizing short-term concerns, such as tariffs, Buffett remains optimistic about the U.S.&#8217;s long-term prospects.&nbsp;
"If I were being born today, I would just keep negotiating in the womb until they said I could be in the United States," stated Buffett while expressing his love for the U.S. as the place of his birth and investment.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/management/25/05/45429435/warren-buffett-explains-why-he-couldnt-deny-greg-abel-the-top-job-at-berkshire-hathaway-any-longer-hes-a-natural" target="_blank" rel="noreferrer noopener">Warren Buffett Explains Why He Couldn&#8217;t Deny Greg Abel The Top Job At Berkshire Hathaway Any Longer: &#8216;He&#8217;s A Natural&#8217; &#8211; Benzinga</a>
Why It Matters:&nbsp;Buffett&#8217;s optimism is backed by his successful investment history. Notably, 98% of his $160 billion wealth was <a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">earned </a>after he turned 65. Buffett&#8217;s company, Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), has also emerged as a significant player in the U.S. Treasury-bill market, with <a href="https://www.benzinga.com/markets/equities/25/05/45342110/warren-buffetts-cash-mountain-grows-to-314-billion-as-berkshire-hathaway-emerges-as-top-treasury-bill-holder-wed-spend-100-billion-if-the-right-deal-came-along">holdings </a>amounting to $314 billion.
Furthermore, Buffett has announced his plans to step down as chief executive in December, <a href="https://www.benzinga.com/news/management/25/05/45429435/warren-buffett-explains-why-he-couldnt-deny-greg-abel-the-top-job-at-berkshire-hathaway-any-longer-hes-a-natural">passing the reins </a>to Greg Abel. This transition is likely to usher in a new era for Berkshire Hathaway, but Buffett&#8217;s faith in the U.S. economy remains a guiding principle.
Buffett admitted he couldn&#8217;t predict short-term stock movements but remained confident that U.S. stocks would eventually continue their long-term upward trend.
The shares of Berkshire Hathaway lost 1.66% to close at $503.40 on Wednesday, while on a year-to-date basis, it surged 11.59%, according to data from<a href="http://pro.benzinga.com"> Benzinga Pro. </a>
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45418628/bitcoin-ethereum-xrp-dogecoin-flat-as-traders-hope-for-altcoin-outperformance" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Flat As Traders Hope For Altcoin Outperformance &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

General

Warren Buffett's Net Worth Secret Is Tied To The 'Luckiest Day' Of His Life: 'If I Were Being Born Today, I Would Just Keep Negotiating In The Womb Until...'

CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) will release its first-quarter earnings results after the <a href="https://www.benzinga.com/quote/CAVA/earnings">closing bell on Thursday, May 15</a>.
Analysts expect the company to report quarterly earnings at 15 cents per share, up from 13 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, CAVA projects quarterly revenue at $327.71 million, compared to $259.01 million a year earlier.
On March 26, S&amp;P Dow Jones Indices said Cava Group will replace Altair Engineering in the S&amp;P MidCap 400.
CAVA shares fell 0.2% to close at $99.54 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/cava/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Dennis Geiger maintained a Neutral rating and cut the price target from $125 to $112 on May 13, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Barclays analyst Jeffrey Bernstein maintained an Equal-Weight rating and slashed the price target from $104 to $90 on April 22, 2025. This analyst has an accuracy rate of 63%.</li>
<li>TD Securities analyst Andrew Charles maintained a Buy rating and cut the price target from $130 to $120 on April 21, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Baird analyst David Tarantino maintained an Outperform rating and slashed the price target from $125 to $105 on April 7, 2025. This analyst has an accuracy rate of 74%.</li>
<li>JP Morgan analyst John Ivankoe upgraded the stock from Neutral to Overweight with a price target of $110 on March 20, 2025. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying CAVA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15025203/image-170-1024x576.png" alt="" class="wp-image-916023" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15025203/image-170-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15025203/image-170-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15025203/image-170-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15025203/image-170.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

CAVA

Top Wall Street Forecasters Revamp CAVA Expectations Ahead Of Q1 Earnings

DTST

Data Storage Q1 2025 EPS $0.00 Misses $0.10 Estimate, Sales $8.08M Miss $8.30M Estimate

WestPark Capital analyst Casey Ryan reiterates Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $2.22 price target.

Reiteration

INVZ

WestPark Capital Reiterates Buy on Innoviz Technologies, Maintains $2.22 Price Target

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Global Medical REIT Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Global Medical REIT reported mixed first-quarter financial results. Jeffrey M. Busch, Chairman, Chief Executive Officer and President stated, &#8220;During the first quarter, we continued to deliver steady results supported by the high quality of our portfolio and stability of our tenant base.&#8221; The company's stock fell around 13% over the past five days and has a 52-week low of $6.58.</li>
<li>RSI Value: 27.3</li>
<li>GMRE Price Action: Shares of Global Medical REIT fell 1.3% to close at $6.70 on Tuesday.</li>
<li>Edge Stock Ratings: 21.25 Momentum score with Value at 50.58. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/GMRE"><img loading="lazy" decoding="async" width="492" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172.png" alt="" class="wp-image-916113" style="width:367px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172.png 492w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172-300x108.png 300w" sizes="(max-width: 492px) 100vw, 492px" /></a></figure>
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Trinseo reported worse-than-expected first-quarter sales results. Frank Bozich, President and Chief Executive Officer of Trinseo, said, &#8220;Core business results in the first quarter were in line with expectations, and sequentially higher due to prior quarter customer destocking and seasonality. Despite persistent market weakness, the first quarter was Trinseo&#8217;s 7th consecutive quarter of year-over-year Adjusted EBITDA improvement driven by the various management actions we took early in this industry downturn.&#8221; The company's stock fell around 31% over the past month and <a href="https://www.benzinga.com/quote/OPI">has a 52-week low</a> of $0.25.</li>
<li>RSI Value: 25.6</li>
<li>OPI Price Action: Shares of Office Properties Income Trust fell 7.5% to close at $0.25 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in OPI <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173.png" alt="" class="wp-image-916114" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Healthpeak Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>)</h3>
<ul class="wp-block-list">
<li>On April 24, Healthpeak Properties posted better-than-expected quarterly sales. The company's stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DOC">low of $16.90</a>.</li>
<li>RSI Value: 25.7</li>
<li>DOC Price Action: Shares of Healthpeak Properties fell 1.6% to close at $16.97 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">DOC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="881" height="816" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174.png" alt="" class="wp-image-916116" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174.png 881w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174-768x711.png 768w" sizes="(max-width: 881px) 100vw, 881px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Photo via Shutterstock

Long Ideas

GMRE

Top 3 Real Estate Stocks You'll Regret Missing This Quarter

Allstate Announces Estimated Catastrophe Losses For The Month Of April Of $594M Or $469M, After-Tax. Catastrophe Losses For April Include 11 Events With ~60% Of The Losses Related To Two Geographically Widespread Wind And Hail Events

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.
Shares of Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://in.benzinga.com/news/earnings/25/05/45421747/red-cat-holdings-q1-earnings-revenue-eps-miss-estimates-drone-maker-affirms-fy25-guidance-highlights-palantir-partnership-shares-slide">quarterly financial results</a>.
Red Cat reported first-quarter revenue of $1.63 million, missing analyst estimates of $3.85 million. The company reported a first-quarter loss of 27 cents per share, missing analyst estimates for a loss of eight cents per share, according to Benzinga Pro.
Red Cat shares tumbled 13.4% to $5.76 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>New Fortress Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>) fell 31.3% to $4.66 in today's pre-market trading after the company reported a first-quarter sales miss.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares tumbled 19.8% to $4.90 in pre-market trading.</li>
<li>DXC Technology Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) declined 15.8% to $13.95 in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter guidance below estimates. Also, the company issued FY26 adjusted EPS guidance below estimates.</li>
<li>Ruanyun Edai Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) shares declined 15.7% to $8.07 in pre-market trading.</li>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares tumbled 12.3% to $17.24 in pre-market trading. The FDA extended PDUFA date of Biohaven&#8217;s Troriluzole NDA for rare disease Spinocerebellar Ataxia.</li>
<li>DICK&#8217;S Sporting Goods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) fell 8% to $192.80 in pre-market trading after the company reported select preliminary financial results for its first quarter.</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) declined 6.1% to $289.25 in pre-market trading.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) fell 5.8% to $126.24 in pre-market trading after the company reported downbeat quarterly revenue.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Movers

BABA

BHVN

RCAT

RYET

SHLS

Red Cat Holdings, Alibaba, DXC Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

JP Morgan analyst Matthew Boss maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and lowers the price target from $209 to $196.

BOOT

JP Morgan Maintains Overweight on Boot Barn Holdings, Lowers Price Target to $196

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham cut Endava plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) price target from $22 to $18. Needham analyst Mayank Tandon maintained a Buy rating. Endava shares closed at $15.64 on Wednesday. See <a href="https://www.benzinga.com/quote/DAVA/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from $72 to $75. Wells Fargo analyst Aaron Rakers upgraded the stock from Equal-Weight to Overweight. Cisco shares closed at $61.29 on Wednesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) price target from $15 to $16. Rosenblatt analyst Barton Crockett maintained a Buy rating. Nexxen International shares closed at $11.62 on Wednesday. <a href="https://www.benzinga.com/quote/NEXN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) from $60 to $70. Needham analyst Bernie McTernan maintained a Buy rating. Ibotta shares closed at $50.13 on Wednesday. <a href="https://www.benzinga.com/quote/IBTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for Grove Collaborative Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) from $2 to $1.2. Telsey Advisory Group analyst Dana Telsey downgraded the stock from Outperform to Market Perform. Grove Collaborative shares closed at $1.19 on Wednesday. See how other analysts vie<a href="https://www.benzinga.com/quote/GROV/analyst-ratings">w this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Sanara MedTech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) price target from $51 to $53. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Sanara MedTech shares settled at $31.30 on Wednesday. <a href="https://www.benzinga.com/quote/SMTI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity slashed Annovis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NASDAQ">ANVS</a>) price target from $26 to $17. Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating. Annovis Bio shares closed at $1.69 on Wednesday. <a href="https://www.benzinga.com/quote/ANVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital cut Metagenomi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) price target from $13 to $12. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Metagenomi shares closed at $1.50 on Wednesday.  <a href="https://www.benzinga.com/quote/MGX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased the price target for Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from $19 to $21. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Levi Strauss shares settled at $17.53 on Wednesday. <a href="https://www.benzinga.com/quote/LEVI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) price target from $70 to $73. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Cisco shares closed at $61.29 on Wednesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LEVI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15083010/image-181-1024x583.png" alt="" class="wp-image-916416" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15083010/image-181-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15083010/image-181-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15083010/image-181-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15083010/image-181.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock"> Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shuttterstock

ANVS

CSCO

DAVA

GROV

IBTA

LEVI

NEXN

SMTI

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Earnings Beats

LTRN

Lantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) is a company that is &#8220;incredibly well-run that has tremendous growth.&#8221; He recommended buying the stock &#8220;given the fact that so many of these other stocks actually even have higher <a href="https://www.benzinga.com/quote/ALAB/earnings">price-to-earnings multiples.&#8221;</a>
Morgan Stanley analyst Joseph Moore supported his view by upgrading the rating for Astera Labs from Equal-Weight to Overweight and maintaining the price target of $99.
When asked about Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), he said, &#8220;I think you're right to be worried.&#8221;
On the earnings front, Omega Healthcare Investors reported quarterly earnings of 75 cents per share on May 1, beating the analyst consensus estimate of 74 cents per share. The company reported quarterly sales of $276.80 million, missing the analyst consensus estimate of $288.69 million.
Price Action:
<ul class="wp-block-list">
<li>Omega Healthcare Investors shares fell 1.4% to settle at $35.91 on Wednesday.</li>
<li>Astera Labs shares rose 3.3% to close at $90.66 during the session.</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

ALAB

Jim Cramer: Astera Labs Has 'Tremendous Growth'

HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) reported quarterly losses of $(0.14) per share. This is a 133.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $3.59 million in sales this quarter. This is a 28.93 percent decrease over sales of $5.05 million the same period last year.

HTCR

HeartCore Enterprises Q1 EPS $(0.14) Down From $(0.06) YoY, Sales $3.59M Down From $5.05M YoY

Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(8.04) by 80.35 percent. This is a 73.31 percent increase over losses of $(5.92) per share from the same period last year. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $60.00 thousand by 5.00 percent. This is a 1.79 percent increase over sales of $56.00 thousand the same period last year.

TRAW

UPDATE: Traws Pharma Q1 Adj. EPS $(1.58) Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate

Press Releases

ThredUp Announces Third Quarter 2024 Results

ThredUp Appoints Danielle Vermeer as Head of Social Commerce

ThredUp Completes Divestiture of European Business

ThredUp to Participate in Needham Conference

ThredUp Provides Preliminary Fourth Quarter 2024 Results, Exceeding Guidance

ThredUp to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ThredUp Announces Fourth Quarter and Full Year 2024 Results

ThredUp's 13th Resale Report Shows Online Resale Saw Accelerated Growth in 2024 and Is Expected to Reach $40 Billion by 2029

ThredUp to Report First Quarter 2025 Financial Results on May 5, 2025

ThredUp Announces First Quarter 2025 Results

TDUP

American Eagle Outfitters, Inc. Common Stock

American Eagle Outfitters

Abercrombie & Fitch

Buckle

Boot Barn Holdings

Burlington Stores

Caleres

Citi Trends

Torrid Holdings

Designer Brands Inc. Class A Common Stock

Designer Brands

Foot Locker

Genesco

Guess

J.Jill

Lands' End

LuxExperience B.V. American Depositary Shares, each representing one Ordinary Share

Comments

ThredUp

ニュース

最新ニュース ThredUp (NASDAQ:TDUP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル